Literature DB >> 35145273

FTO promotes Bortezomib resistance via m6A-dependent destabilization of SOD2 expression in multiple myeloma.

Chong Wang1, Lingling Li2, Mengya Li2, Weiqiong Wang2, Zhongxing Jiang2.   

Abstract

Drug resistance is the main reason for the failure of Bortezomib (Bort) in the treatment of multiple myeloma (MM), which seriously affects the efficacy of Bort. Therefore, the exploration of Bort resistance to treat MM will be very beneficial. Thus, this study aims to study the function and mechanism of Fat mass and obesity associated (FTO) on the Bort resistance of MM. In the present study, we demonstrated that FTO promotes Bort resistance via m6A-dependent destabilization of SOD2 expression in MM. These findings may provide a substantial evidence for the Bort resistance in MM.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Year:  2022        PMID: 35145273     DOI: 10.1038/s41417-022-00429-6

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  4 in total

Review 1.  [Progress in epigenetic modification of mRNA and the function of m6A modification].

Authors:  Haili Gan; Ling Hong; Fenglian Yang; Dingfeng Liu; Liping Jin; Qingliang Zheng
Journal:  Sheng Wu Gong Cheng Xue Bao       Date:  2019-05-25

Review 2.  The Diagnosis and Treatment of Multiple Myeloma.

Authors:  Christian Gerecke; Stephan Fuhrmann; Susanne Strifler; Martin Schmidt-Hieber; Hermann Einsele; Stefan Knop
Journal:  Dtsch Arztebl Int       Date:  2016-07-11       Impact factor: 5.594

Review 3.  Multiple myeloma: from diagnosis to treatment.

Authors:  Renee Eslick; Dipti Talaulikar
Journal:  Aust Fam Physician       Date:  2013-10

4.  The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells.

Authors:  Kosuke Taketo; Masamitsu Konno; Ayumu Asai; Jun Koseki; Masayasu Toratani; Taroh Satoh; Yuichiro Doki; Masaki Mori; Hideshi Ishii; Kazuhiko Ogawa
Journal:  Int J Oncol       Date:  2017-12-07       Impact factor: 5.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.